Top Tech Companies (84)
At Nimbus, we design breakthrough medicines. Utilizing our powerful structure-based drug discovery engine, we create potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. With a decade-plus track record of success, we’ve built a world-class team in both computationally driven drug discovery and early clinical development while continuing to move the needle for patients.
Labviva is the SaaS digital marketplace that connects suppliers, purchasers, and scientists. Our platform seamlessly integrates with your existing procurement systems, to enable purchasing departments to take control of their supply chain by gaining greater visibility of purchasing trends and third-party tail spend, while providing a comprehensive customized marketplace that streamlines the purchasing process with existing workflows. We strive to connect researchers with suppliers of reagents, chemicals, and instrumentation in an intuitive user-friendly platform that supports the priorities of scientists while staying compliant with purchasing rules. Suppliers can easily manage their content of their products. Products are mapped into scientific applications, techniques and protocols, then a relevant a citation index score is generated based on references in peer reviewed journal and related documents and assets are compiled. The results are a unique index of products linked to the relevancy of a product with each scientific use case.
At Akili, we’re creating personalized digital therapeutics engineered to directly improve cognitive impairments. Our medicines look and feel like high-end interactive action video games but, unlike typical video games, they are informed by decades of neuroscience and built with proprietary technology developed to target and treat cognitive impairments at their specific sources in the brain. Not only is our medicine designed to target the areas of your brain that need it most, it’s designed specifically for you, adapting based on your individual needs.
SmartLabs is accelerating the pace of scientific discovery by radically transforming the way the world builds and uses lab space. Where lab construction can take 9 to 12 months in the traditional process, we deliver personalized and effective lab workflow environments in about 4 weeks. This huge reduction in time means member teams are starting sooner and results are delivered faster. We continue to compound this time savings with our proactive operational support and ability to pivot and change lab space quickly as member science evolves and lab needs change. We love what we do - our members are shaping the future and we are proud to help them do it! We currently have locations in the MIT area of Cambridge, at Innovation Square in the Boston Seaport, in the hot new development at Boston Landing, and in South San Francisco. Visit our website to request a tour.
Seven Bridges is the biomedical data analysis company accelerating breakthroughs in genomics research for cancer, drug development and precision medicine. We democratize genomics by enabling researchers anywhere to process and understand genomic data faster and more efficiently than ever, at any scale. Thousands of researchers in government, biotech, pharmaceutical and academic labs use Seven Bridges, including three of the largest genomics projects in the world: U.S. National Cancer Institute’s Cancer Genomics Cloud pilot, honored with the Bio-IT World Best of Show award 2016, the Million Veteran Program, and Genomics England’s 100,000 Genomes Project. As the NIH’s only commercial Trusted Partner, Seven Bridges authenticates and authorizes access to one of the world’s largest cancer genomics dataset. Seven Bridges has been recognized by the MIT Technology Review as one of the Top 50 Smartest Companies in the World in 2016.
Accent is leading the translation of RNA-modifying protein (RMP) biology into promising new therapies by combining a robust chemical biology platform with rigorous approaches to target identification and validation. Our seasoned team of drug developers is uniquely experienced to interrogate and advance small molecule therapies with far-reaching potential.
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.
A TARGETED APPROACH TO ACTIVATE CELLULAR CLEARANCE Caraway’s therapeutic approach leverages genetic data and unique biological understanding to develop proprietary small molecules that activate cellular clearance and recycling processes – accelerating clearance of accumulated toxic materials and defective cellular components. New insights in genetics highlight the link between lysosomal function and pathologies in multiple organ systems, including the central nervous system (CNS), heart, kidney, and muscle. Caraway is a leader in targeting these mechanisms with potentially disease-modifying compounds for patients suffering the devastating effects of neurodegenerative and rare diseases including Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and lysosomal storage diseases (LSDs).
At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).
Reverie Labs is a pharmaceutical company that uses its innovative computational chemistry and machine learning tools to accelerate its drug discovery programs. Reverie's primary goal is to develop kinase inhibitors that address the unmet needs of patients.
REGENHU is a provider of 3D Bioprinters, and has developed, manufactured and distributed innovative hardware and software tools for 3D Bioprinting applications since 2007. We are a pioneer in the field and our global customer portfolio comprises leading universities as well as key players in the biotech industry, pharma, cosmetics, and MedTech. We are rapidly expanding our world class team of talented individuals who are willing to go above and beyond to always provide our customer with the best. To learn more, please visit our website www.regenhu.com
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.
Ultromics is a global health technology firm which provides autonomous echocardiography analysis through innovative AI solutions empowering physicians to make fast, accurate decisions when diagnosing cardiovascular disease. We have developed EchoGo, the world’s first autonomous echocardiography service which provides cloud-based artificial intelligence services to support cardiac imaging diagnosis without any variability or need to touch software. Our technology was born at the University of Oxford and built in partnership with the NHS, and has since raised over £20 million to help improve patient care, and bring diagnostic quality and resource savings to hospitals. Cardiovascular disease is the leading cause of mortality, with an estimated 17 million deaths each year. For more information about Ultromics - http://www.ultromics.com/
Pear Therapeutics’ patented eFormulation approach combines mobile health apps with supplements, medical foods, and pharmaceuticals, to create more efficacious treatment solutions. eFormulations are simple to use. A software access code on the product packaging provides access to Pear’s health apps. The patient takes the supplement or prescribed medication and simultaneously uses Pear’s games and apps, increasing efficacy, improving side effects, and enhancing compliance. Pear’s eFormulations are the only way to target both brain chemistry and cognitive experience simultaneously, providing an entirely new way to treat brain-related diseases.
Medidata is leading the digital transformation of life sciences with the world's most-used platform for clinical development, commercial and real-world data. Powered by artificial intelligence and delivered by #1 ranked industry experts, the Intelligent Platform for Life Sciences helps pharmaceutical, biotech, medical device companies and academic
We've experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, we've developed a simple blood test uncovers actionable disease-defining transcriptional biology. Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma. By partnering with developers of new medicines and advancing our own diagnostic tests, we’re working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that’s precise to the biology of their disease.
At PathAI our mission is to improve patient outcomes with AI-powered technology. PathAI’s platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning.
High Touch Group is a privately held consultancy that helps science, engineering, and technology clients market existing products and services, showcase their value, develop and launch new products, engage with investors, generate leads, and drive revenue. We keep the science and make it exciting.
Scorpion Therapeutics was founded to expand the reach of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0, a pipeline of targeted small-molecule drugs that overcome the limitations of existing treatments. Scorpion’s experienced leadership team is executing a fit-to-purpose model to efficiently unlock the next generation of precision oncology. For more information, visit scorpiontx.com.
Volta Labs is a collective of antidisciplinary scientists and builders working at the intersection of engineering and biology. Our mission is clear: unlock the utility of genomics for the world. To do this, we’re building a sequencing technology agnostic platform that revolutionizes the entire sample prep process — from raw biological samples to sequenceable molecules. This makes an imagined world in which a single instrument automates the majority of biological workflows done in a lab into a reality. Our platform can handle a wide range of raw biological samples and deliver sequenceable molecules - all at the push of a button. This has required reinventing the full stack of technologies – hardware, software, chemistry, and biology.
